Anti-inflammatory effects of arsenic trioxide eluting stents in a porcine coronary model

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Shen, Li ^a   Gong, Feirong ^b   Tian, Wenjie ^c   Li, Weiming ^d   Zhang, Feng ^a   Qian, Juying ^a   Sun, Aijun ^a   Zou, Yunzeng ^a   Yang, Wei ^d   Ge, Junbo ^a  

^a FUDAN UNIVERSITY   (China)

^b East China University of Science and Technology   (China)

^c SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ARSENIC TRIOXIDE; ANTIINFLAMMATORY AGENT; ORGANOARSENIC DERIVATIVE; OXIDE; POLYMER;

ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; ARTERY ENDOTHELIUM; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; NEOINTIMA; NONHUMAN; SPECTROFLUOROMETRY; SURFACE PROPERTY; SWINE; WESTERN BLOTTING; ANIMAL; APOPTOSIS; CELL CYCLE; CHEMISTRY; CORONARY BLOOD VESSEL; HEART; HEART MUSCLE; INFLAMMATION; INTIMA; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; ARSENICALS; CELL CYCLE; CORONARY VESSELS; DRUG-ELUTING STENTS; HEART; INFLAMMATION; MALE; MYOCARDIUM; OXIDES; POLYMERS; SWINE; TUNICA INTIMA;

EID: 84874591071     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/937936     Document Type: Article

References (48)

1. Sousa J. E., Costa M. A., Sousa A. G. M. R., Abizaid A. C., Seixas A. C., Abizaid A. S., Feres F., Mattos L. A., Falotico R., Jaeger J., Popma J. J., Serruys P. W., Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003 107 3 381 383 2-s2.0-0037469230 10.1161/01.CIR.0000051720. 59095.6D (Pubitemid 36158039)
2. Stone G. W., Ellis S. G., Cox D. A., Hermiller J. A., O'Shaughnessy C., Mann J. T., Turco M., Caputo R., Bergin P., Greenberg J., Popma J. J., Russell M. E., A Polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. The New England Journal of Medicine 2004 350 3 221 231 2-s2.0-9144249927 10.1056/NEJMoa032441 (Pubitemid 38067635)
3. Kastrati A., Mehilli J., Pache J., Kaiser C., Valgimigli M., Kelbæk H., Menichelli M., Sabaté M., Suttorp M. J., Baumgart D., Seyfarth M., Pfisterer M. E., Schömig A., Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. The New England Journal of Medicine 2007 356 10 1030 1039 2-s2.0-33847766568 10.1056/NEJMoa067484 (Pubitemid 46376803)
4. Lagerqvist B., James S. K., Stenestrand U., Lindbäck J., Nilsson T., Wallentin L., Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. The New England Journal of Medicine 2007 356 10 1009 1019 2-s2.0-33847762819 10.1056/NEJMoa067722 (Pubitemid 46376801)
5. Maisel W. H., Unanswered questions: drug-eluting stents and the risk of late thrombosis. The New England Journal of Medicine 2007 356 10 981 984 2-s2.0-33847723010 10.1056/NEJMp068305 (Pubitemid 46376797)
6. Farb A., Weber D. K., Kolodgie F. D., Burke A. P., Virmani R., Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002 105 25 2974 2980 2-s2.0-0037172986 10.1161/01.CIR.0000019071. 72887.BD (Pubitemid 34693829)
7. Kotani J. I., Awata M., Nanto S., Uematsu M., Oshima F., Minamiguchi H., Mintz G. S., Nagata S., Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. Journal of the American College of Cardiology 2006 47 10 2108 2111 2-s2.0-33646252464 10.1016/j.jacc.2005.11.092
8. Wilson G. J., Nakazawa G., Schwartz R. S., Huibregtse B., Poff B., Herbst T. J., Baim D. S., Virmani R., Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation 2009 120 2 141 149 2-s2.0-67651119696 10.1161/ CIRCULATIONAHA.107.730010
9. Hofma S. H., van der Giessen W. J., van Dalen B. M., Lemos P. A., McFadden E. P., Sianos G., Ligthart J. M. R., Van Essen D., De Feyter P. J., Serruys P. W., Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. European Heart Journal 2006 27 2 166 170 2-s2.0-30344439818 10.1093/eurheartj/ehi571 (Pubitemid 43069032)
10. Finn A. V., Joner M., Nakazawa G., Kolodgie F., Newell J., John M. C., Gold H. K., Virmani R., Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007 115 18 2435 2441 2-s2.0-34248219973 10.1161/CIRCULATIONAHA.107.693739 (Pubitemid 46717966)
11. Finn A. V., Nakazawa G., Joner M., Kolodgie F. D., Mont E. K., Gold H. K., Virmani R., Vascular responses to drug eluting stents: importance of delayed healing. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 7 1500 1510 2-s2.0-34250835092 10.1161/ATVBAHA.107.144220 (Pubitemid 46986103)
12. Ako J., Morino Y., Honda Y., Hassan A., Sonoda S., Yock P. G., Leon M. B., Moses J. W., Bonneau H. N., Fitzgerald P. J., Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. Journal of the American College of Cardiology 2005 46 6 1002 1005 2-s2.0-24944585578 10.1016/j.jacc.2005.05.068 (Pubitemid 41316506)
13. Joner M., Finn A. V., Farb A., Mont E. K., Kolodgie F. D., Ladich E., Kutys R., Skorija K., Gold H. K., Virmani R., Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. Journal of the American College of Cardiology 2006 48 1 193 202 2-s2.0-33745233024 10.1016/j.jacc.2006. 03.042 (Pubitemid 43929240)
14. Lüscher T. F., Steffel J., Eberli F. R., Joner M., Nakazawa G., Tanner F. C., Virmani R., Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007 115 8 1051 1058 2-s2.0-33847259689 10.1161/CIRCULATIONAHA.106.675934 (Pubitemid 46328299)
15. Ako J., Bonneau H. N., Honda Y., Fitzgerald P. J., Design criteria for the ideal drug-eluting stent. The American Journal of Cardiology 2007 100 8 S3 S9 2-s2.0-35348879238 10.1016/j.amjcard.2007.08.016 (Pubitemid 47576034)
16. Zhang P., Wang S. Y., Hu L. H., Treatment of acute promyelocytic leukemia with intravenous arsenic trioxide. Chinese Journal of Hematology 1996 17 58 60
17. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML- RAR α /PML proteins. Blood 1996 88 3 1052 1061 2-s2.0-0010740572 (Pubitemid 26333331)
18. Pelicano H., Feng L., Zhou Y., Carew J. S., Hileman E. O., Plunkett W., Keating M. J., Huang P., Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. Journal of Biological Chemistry 2003 278 39 37832 37839 2-s2.0-0141509869 10.1074/jbc.M301546200 (Pubitemid 37175311)
19. Kang Y. H., Yi M. J., Kim M. J., Park M. T., Bae S., Kang C. M., Cho C. K., Park I. C., Park M. J., Rhee C. H., Hong S. I., Chung H. Y., Lee Y. S., Lee S. J., Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria. Cancer Research 2004 64 24 8960 8967 2-s2.0-10844264632 10.1158/0008-5472.CAN-04-1830 (Pubitemid 39665504)
20. Diaz Z., Colombo M., Mann K. K., Su H., Smith K. N., Bohle D. S., Schipper H. M., Miller W. H., Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines. Blood 2005 105 3 1237 1245 2-s2.0-12844254279 10.1182/blood-2004-05-1772 (Pubitemid 40170899)
21. Baumgartner M., Sturlan S., Roth E., Wessner B., Bachleitner-Hofmann T., Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells. International Journal of Cancer 2004 112 4 707 712 2-s2.0-7044234956 10.1002/ijc.20462 (Pubitemid 39425954)
22. Zhu X. H., Shen Y. L., Jing Y. K., Cai X., Jia P. M., Huang Y., Tang W., Shi G. Y., Sun Y. P., Dai J., Wang Z. Y., Chen S. J., Zhang T. D., Waxman S., Chen Z., Chen G. Q., Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. Journal of the National Cancer Institute 1999 91 9 772 778 2-s2.0-0033526358 (Pubitemid 29239056)
23. Miller W. H. Jr., Schipper H. M., Lee J. S., Singer J., Waxman S., Mechanisms of action of arsenic trioxide. Cancer Research 2002 62 14 3893 3903 2-s2.0-0037099645 (Pubitemid 34792653)
24. Roboz G. J., Dias S., Lam G., Lane W. J., Soignet S. L., Warrell R. P., Rafii S., Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000 96 4 1525 1530 2-s2.0-0034663032 (Pubitemid 30658486)
25. Yang W., Ge J. B., Liu H. L., Zhao K., Liu X. B., Qu X. F., Li W. M., Huang Y. L., Sun A., Zou Y., Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model. Cardiovascular Research 2006 72 3 483 493 2-s2.0-33750519849 10.1016/j.cardiores.2006.08.010 (Pubitemid 44665846)
26. Kornowski R., Hong M. K., Tio F. O., Bramwell O., Wu H., Leon M. B., In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. Journal of the American College of Cardiology 1998 31 1 224 230 2-s2.0-0031885670 10.1016/S0735-1097(97)00450-6 (Pubitemid 28064746)
27. Li J. J., Li J., Nan J. L., Li Z., Zhen X., Mu C. W., Dai J., Zhang C. Y., Coronary restenotic reduction of drug-eluting stenting may be due to its anti-inflammatory effects. Medical Hypotheses 2007 69 5 1004 1009 2-s2.0-34548802344 10.1016/j.mehy.2007.01.090 (Pubitemid 47430235)
28. Gaspardone A., Versaci F., Coronary stenting and inflammation. The American journal of cardiology. 2005 96 12 A 65L 70L 2-s2.0-33644864730
29. Li J. J., Nie S. P., Zhang C. Y., Gao Z., Zheng X., Guo Y. L., Is inflammation a contributor for coronary stent restenosis? Medical Hypotheses 2007 68 5 945 951 2-s2.0-33847023000 10.1016/j.mehy.2006.05.069 (Pubitemid 46274028)
30. Dibra A., Mehilli J., Braun S., Hadamitzky M., Baum H., Dirschinger J., Schühlen H., Schömig A., Kastrati A., Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. The American Heart Journal 2005 150 2 344 350 2-s2.0-23644455687 10.1016/j.ahj.2004.09.030 (Pubitemid 41116262)
31. Farb A., Sangiorgi G., Carter A. J., Walley V. M., Edwards W. D., Schwartz R. S., Virmani R., Pathology of acute and chronic coronary stenting in humans. Circulation 1999 99 1 44 52 2-s2.0-0033547812 (Pubitemid 29035956)
32. Grewe P. H., Deneke T., Machraoui A., Barmeyer J., Müller K. M., Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. Journal of the American College of Cardiology 2000 35 1 157 163 2-s2.0-0033984273 10.1016/S0735-1097(99)00486-6 (Pubitemid 30061274)
33. Glover C., Ma X., Chen Y. X., Miller H., Veinot J., Labinaz M., O'Brien E., Human in-stent restenosis tissue obtained by means of coronary atherectomy consists of an abundant proteoglycan matrix with a paucity of cell proliferation. The American Heart Journal 2002 144 4 702 709 2-s2.0-0036791082 10.1016/S0002-8703(02)00145-X
34. Chung I. M., Gold H. K., Schwartz S. M., Ikari Y., Reidy M. A., Wight T. N., Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. Journal of the American College of Cardiology 2002 40 12 2072 2081 2-s2.0-0037132676 10.1016/S0735-1097(02)02598-6 (Pubitemid 36005890)
35. Welt F. G., Rogers C., Inflammation and restenosis in the stent era. Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 11 1769 1776 2-s2.0-0036845123 10.1161/01.ATV.0000037100.44766.5B (Pubitemid 35315761)
36. Colombo A., Sangiorgi G., The Monocyte: the key in the lock to reduce stent hyperplasia? Journal of the American College of Cardiology 2004 43 1 24 26 2-s2.0-0345791416 10.1016/j.jacc.2003.10.015 (Pubitemid 38045909)
37. Gong F. R., Cheng X. Y., Wang S. F., Zhao Y. C., Gao Y., Cai H. B., Heparin-immobilized polymers as non-inflammatory and non-thrombogenic coating materials for arsenic trioxide eluting stents. Acta Biomaterialia 2010 6 2 534 546 2-s2.0-72049107725 10.1016/j.actbio.2009.07.013
38. Bräsen J. H., Kivelä A., Röser K., Rissanen T. T., Niemi M., Luft F. C., Donath K., Ylä-Herttuala S., Angiogenesis, vascular endothelial growth factor and platelet-derived growth factor-BB expression, iron deposition, and oxidation-specific epitopes in stented human coronary arteries. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 11 1720 1726 2-s2.0-0035569982 (Pubitemid 34219773)
39. Scott N. A., Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular responses to injury. Advanced Drug Delivery Reviews 2006 58 3 358 376 2-s2.0-33744508973 10.1016/j.addr.2006.01.015 (Pubitemid 43816739)
40. Suzuki T., Kopia G., Hayashi S. I., Bailey L. R., Llanos G., Wilensky R., Klugherz B. D., Papandreou G., Narayan P., Leon M. B., Yeung A. C., Tio F., Tsao P. S., Falotico R., Carter A. J., Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001 104 10 1188 1193 2-s2.0-0035806921 (Pubitemid 32830406)
41. Blum A., Schneider D. J., Sobel B. E., Dauerman H. L., Endothelial dysfunction and inflammation after percutaneous coronary intervention. The American Journal of Cardiology 2004 94 11 1420 1423 2-s2.0-9344248394 10.1016/j.amjcard.2004.07.146 (Pubitemid 39556215)
42. Li J. S., Jabara R., Pendyala L., Otsuka Y., Shinke T., Hou D., Robinson K., Chronos N., Abnormal vasomotor function of porcine coronary arteries distal to sirolimus-eluting stents. Journal of American College of Cardiology 2008 1 3 279 285 2-s2.0-44949263884 10.1016/j.jcin.2008.01.009 (Pubitemid 351804187)
43. Werner N., Junk S., Laufs U., Link A., Walenta K., Bohm M., Nickenig G., Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circulation research 2003 93 2 e17 e24 2-s2.0-0041733082
44. Kong D., Melo L. G., Mangi A. A., Zhang L., Lopez-Ilasaca M., Perrella M. A., Liew C. C., Pratt R. E., Dzau V. J., Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 2004 109 14 1769 1775 2-s2.0-16544390737 10.1161/01.CIR.0000121732.85572.6F (Pubitemid 38500680)
45. Kim J. W., Suh S. Y., Choi C. U., Na J. O., Kim E. J., Rha S. W., Park C. G., Seo H. S., Oh D. J., Six-month comparison of coronary endothelial dysfunction associated with Sirolimus-eluting stent versus paclitaxel-eluting stent. Journal of American College of Cardiology 2008 1 1 65 71 2-s2.0-41249089935 10.1016/j.jcin.2007.11.002 (Pubitemid 351445416)
46. Kim J. W., Seo H. S., Park J. H., Na J. O., Choi C. U., Lim H. E., Kim E. J., Rha S. W., Park C. G., Oh D. J., A Prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent. Journal of the American College of Cardiology 2009 53 18 1653 1659 2-s2.0-65249101325 10.1016/j.jacc.2009.01.051
47. Dominik B., Peter G., Endothelial function: from vascular biology to clinical applications. The American Journal of Cardiology 2002 90 10 40L 48L 2-s2.0-0037153047
48. Grube E., Sonoda S., Ikeno F., Honda Y., Kar S., Chan C., Gerckens U., Lansky A. J., Fitzgerald P. J., Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004 109 18 2168 2171 2-s2.0-2442507751 10.1161/01.CIR.0000128850. 84227.FD (Pubitemid 38625391)